LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Aktien・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Open

Branche Gesundheitswesen

63.1 1.25

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

62.36

Max

63.37

Schlüsselkennzahlen
By Trading Economics
Einkommen	16M 93M
Verkäufe	35M 231M
KGV Branchendurchschnitt	21.73 103.001
EPS	0.91
Gewinnspanne	40.366
Angestellte	373
EBITDA	22M 143M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	-3.16 downside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Nov. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	262M 8.1B
Vorheriger Eröffnungskurs	61.85
Vorheriger Schlusskurs	63.1

Nachrichtenstimmung

By Acuity

50%

97 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

58.94 / 64.3 Unterstützung & Widerstand

Halozyme Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Sept. 2024, 01:45 UTC

Ergebnisse

Preview -- Barron's

13. Sept. 2024, 20:03 UTC

Top News

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15. Sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15. Sept. 2024, 16:52 UTC

Top News

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15. Sept. 2024, 09:30 UTC

Top News

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15. Sept. 2024, 07:00 UTC

Top News

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14. Sept. 2024, 14:09 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14. Sept. 2024, 13:25 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ -2-

14. Sept. 2024, 00:01 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13. Sept. 2024, 21:14 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13. Sept. 2024, 21:06 UTC

Top News

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13. Sept. 2024, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13. Sept. 2024, 20:41 UTC

Top News

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13. Sept. 2024, 20:31 UTC

Ergebnisse

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13. Sept. 2024, 20:13 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13. Sept. 2024, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13. Sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13. Sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13. Sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Peer-Vergleich

Kursveränderung

Halozyme Therapeutics Inc Prognose

Kursziel

By TipRanks

-3.16% Nachteil

12-Monats-Prognose

Durchschnitt 60.33 USD -3.16%

Hoch 72 USD

Tief 51 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Halozyme Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Halozyme Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

58.94 / 64.3Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Stimmung

By Acuity

97 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.